Antengene Corporation and UCB have announced a significant licensing agreement valued at up to $1.18 billion, aimed at advancing the development of ATG-201, an innovative bispecific T-cell engager therapy. This collaboration focuses on addressing B cell-driven autoimmune diseases, highlighting the potential for groundbreaking treatments in immunology.
Strategic Partnership
Dr. Jay Mei, the founder and CEO of Antengene, expressed enthusiasm about the partnership. He emphasized the combination of Antengene’s innovative discovery platform and clinical execution capabilities with UCB’s extensive experience in immunology. This fusion aims to expedite the global development of ATG-201, ensuring efficient progress in bringing this therapy to market.
Mechanism of Action
ATG-201 is engineered to target CD19, a protein found on B cells, directing the body’s T cells to eliminate these cells involved in autoimmune disorders and certain blood cancers. The therapy employs advanced steric hindrance masking technology, designed to enhance tolerability and minimize the risk of cytokine release syndrome (CRS), a severe immune reaction that can occur with T-cell engager therapies.
Upcoming Clinical Trials
Antengene plans to initiate clinical trial applications in China and Australia by the first quarter of 2026. The company aims to complete the first-in-human Phase I studies in both countries before transferring further development responsibilities to UCB. This structured approach ensures that the therapy is rigorously tested, paving the way for subsequent phases of development.
Licensing Agreement Details
Under the terms of the licensing agreement, UCB gains exclusive worldwide rights to develop, manufacture, and commercialize ATG-201. This includes access to Antengene’s manufacturing technology. Antengene will receive an upfront payment of $80 million, which consists of an initial $60 million followed by up to $20 million based on near-term milestones. Furthermore, the agreement opens the door to potential future payments exceeding $1.1 billion tied to development and commercial milestones, in addition to tiered royalties on net sales.
Expanding Therapeutic Horizons
This collaboration allows Antengene to leverage UCB’s global reach and expertise in immunology, significantly enhancing the prospects for ATG-201’s development. For UCB, the agreement marks an expansion beyond traditional monoclonal antibodies into the promising realm of bispecific T-cell engagers, diversifying their therapeutic portfolio.
Promising Preclinical Data
The agreement builds on encouraging preclinical findings of ATG-201, presented at the 2025 American College of Rheumatology Annual Meeting. The data indicated that ATG-201 achieved complete and sustained B cell depletion in humanized mouse models after a single dose, with significantly lower cytokine release compared to benchmark T-cell engagers. This suggests a favorable safety profile and the potential for more durable treatment effects.
Potential Impact on Treatment
The therapy’s ability to mitigate T-cell exhaustion—a common limitation of early T-cell engagers—could lead to a more sustained therapeutic effect. In non-human primate studies, a surrogate version of ATG-201 demonstrated profound B cell depletion with only a mild and transient increase in cytokine levels, further supporting its safety and efficacy.
Conclusion
The partnership between Antengene and UCB represents a transformative step in the development of bispecific T-cell engagers, with ATG-201 positioned as a potential game-changer in the treatment of autoimmune diseases. As both companies work together to advance this innovative therapy, they pave the way for new therapeutic strategies that could redefine patient care in immunology.
- Key Takeaways:
- The partnership is valued at up to $1.18 billion, emphasizing the significance of ATG-201.
- ATG-201 targets CD19, aiming to eliminate B cells involved in autoimmune disorders.
- The therapy utilizes advanced technology to reduce the risk of adverse immune reactions.
- Clinical trials are set to begin in China and Australia by early 2026.
- This collaboration expands UCB’s capabilities into bispecific T-cell engagers, enhancing their portfolio.
Read more → www.pharmexec.com